Calcitriol Trial Investigates Vitamin D's Role in Sepsis Outcomes

Observational studies have consistently linked vitamin D deficiency to worse outcomes in critically-ill patients with conditions like sepsis, including increased length of stay, infection rates, and mortality. However, it remains unclear whether this deficiency directly contributes to adverse outcomes or merely serves as a biomarker of illness severity. This randomized controlled trial aims to determine if administering activated vitamin D (calcitriol) can improve host defense by increasing cathelicidin levels in patients with severe sepsis or septic shock.

The provided abstract details the study's design and hypothesis but does not include the results or specific findings. The primary hypothesis was that Calcitriol administration would lead to an increase in serum levels of cathelicidin, a key anti-microbial peptide. The study was designed to quantitatively compare the change in cathelicidin levels between the Calcitriol group and the placebo group, aiming to show a significant difference. > The central aim was to test if activated vitamin D could directly stimulate the production of cathelicidin, thereby enhancing the immune response in sepsis. Without the results, it is not possible to report specific data such as p-values, fold-changes, or percentages of improvement. The study sought to determine if cathelicidin levels would be significantly higher in the treatment group compared to control, potentially demonstrating a positive effect.